Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Mr. Hao  Pan M.Sc.

Senior Vice President of the Branded Products Business Division & Member of the Exe. Mgmt. Board

Mr. Rene  Lindell M.Sc., Ph.D.

Chief Financial Officer & Member of Group Executive Management Board

Ms. Satu  Ahomäki M.Sc., M.Sc. (Econ.)

Senior Vice President of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board

Ms. Julia Irene Macharey

Senior Vice President of People & Culture and Member of Management Board

Mr. Tuukka  Hirvonen M.Sc.(Soc.)

Investor Relations & Financial Communications Officer

Dr. Liisa  Hurme

President, Chief Executive Officer & Chairman of Executive Management Board

Mr. Olli  Huotari Ll.M.

Senior Vice President of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board

Mr. Niclas  Lindstedt EMBA, M.Sc.

Senior Vice President of Animal Health Business Division & Member of the Exe. Mgmt. Board

Prof. Outi  Vaarala M.D., Ph.D.

Senior Vice President of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board

Mr. Juhani  Kankaanpaa

Senior Vice President of Global Operations & Member of Executive Management Board

Nome	Capitalizzazione di mercato
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Bristol-Myers Squibb Company	0M
Chugai Pharmaceutical Co., Ltd.	0M
Novartis AG	0M

Orion Oyj

Orion Oyj Elenco dei concorrenti

Principali concorrenti